Letter to the Editor
Split Viewer
Blood Res 2014; 49(1):
Published online March 31, 2014
https://doi.org/10.5045/br.2014.49.1.65
© The Korean Society of Hematology
Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy
Hematology Division, S. Eugenio Hospital, Rome, Italy.
Correspondence to : Pasquale Niscola. Hematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Parikh, SA, Tefferi, A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol, 2012;87;610-619.
- Courville, EL, Wu, Y, Kourda, J, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol, 2013;26;751-761.
- Breccia, M, Voso, MT, Alimena, G. Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?. Leuk Res, 2013;37;204-205.
- Kim, YJ, Jang, JH, Kwak, JY, Lee, JH, Kim, HJ. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. Blood Res, 2013;48;87-98.
- Wijermans, PW, Ruter, B, Baer, MR, Slack, JL, Saba, HI, Lubbert, M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res, 2008;32;587-591.
- Onida, F, Kantarjian, HM, Smith, TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 2002;99;840-849.
- Thorpe, M, Montalvao, A, Pierdomenico, F, Moita, F, Almeida, A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res, 2012;36;1071-1073.
- Costa, R, Abdulhaq, H, Haq, B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer, 2011;117;2690-2696.
- Fianchi, L, Criscuolo, M, Breccia, M, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma, 2013;54;658-661.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2014; 49(1): 65-66
Published online March 31, 2014 https://doi.org/10.5045/br.2014.49.1.65
Copyright © The Korean Society of Hematology.
Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy
Pasquale Niscola*, Andrea Tendas, Laura Scaramucci, Marco Giovannini, Daniela Piccioni, and Paolo de Fabritiis
Hematology Division, S. Eugenio Hospital, Rome, Italy.
Correspondence to: Pasquale Niscola. Hematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Parikh, SA, Tefferi, A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol, 2012;87;610-619.
- Courville, EL, Wu, Y, Kourda, J, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol, 2013;26;751-761.
- Breccia, M, Voso, MT, Alimena, G. Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?. Leuk Res, 2013;37;204-205.
- Kim, YJ, Jang, JH, Kwak, JY, Lee, JH, Kim, HJ. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. Blood Res, 2013;48;87-98.
- Wijermans, PW, Ruter, B, Baer, MR, Slack, JL, Saba, HI, Lubbert, M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res, 2008;32;587-591.
- Onida, F, Kantarjian, HM, Smith, TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 2002;99;840-849.
- Thorpe, M, Montalvao, A, Pierdomenico, F, Moita, F, Almeida, A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res, 2012;36;1071-1073.
- Costa, R, Abdulhaq, H, Haq, B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer, 2011;117;2690-2696.
- Fianchi, L, Criscuolo, M, Breccia, M, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma, 2013;54;658-661.
Previous Article
